-
1 Comment
CorMedix Inc is currently in a long term downtrend where the price is trading 21.0% below its 200 day moving average.
From a valuation standpoint, the stock is 12.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1149.8.
CorMedix Inc's total revenue rose by 124.9% to $56K since the same quarter in the previous year.
Its net income has dropped by 14.8% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 54.3% to $-6M since the same quarter in the previous year.
Based on the above factors, CorMedix Inc gets an overall score of 2/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | US21900C3088 |
| CurrencyCode | EUR |
| Exchange | F |
| Target Price | 21.25 |
|---|---|
| PE Ratio | None |
| Beta | 2.22 |
| Market Cap | 209M |
| Dividend Yield | 0.0% |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 19KA.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
